Denosumab (Xgeva®)

Newfoundland & LabradorCommon name: Denosumab
Brand name: Xgeva®

What is Denosumab?

Denosumab is a monoclonal antibody that is used to treat osteoporosis in men diagnosed with prostate cancer. Denosumab works by stopping bone cells (osteoclasts) from breaking down bone structure.

How is Denosumab administered?

Denosumab is administered by subcutaneous injection (under the skin).

What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received denosumab. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Diarrhea
  • Fatigue
  • Nausea
  • Rash
  • Skin changes
  • Weakness

Is Denosumab covered in my province or territory?

Denosumab is covered by provincial drug programs in:
  • British Columbia
  • Manitoba
  • New Brunswick
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
Denosumab is not covered by provincial drug programs in:
  • Alberta
  • Newfoundland & Labrador
  • Northwest Territories
  • Prince Edward Island
  • Yukon
​Unknown if denosumab is covered by provincial drug programs in:
  • ​Nunavut

VICTORY Program – Supportive Care (XGEVA)
Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Please call 1-888-706-4717 for more information and to see if you qualify for this program.

Last Reviewed: July 2017

Donate Now!

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.

Click here for news archive